Featured

• • 

    

    Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)

    Peer

  • 

    

    Javier Morales, MD, FACP, FACE

    Peer

  • 

    

    Angela Yee-Moon Wang, MD, FACP, FACE

    Peer

  10

  

  RestartResume

  A New Option for Cardiorenal Protection for Patients with CKD in T2D

  RestartResume

  A New Option for Cardiorenal Protection for Patients with CKD in T2D

  0.25 credits

  A New Option for Cardiorenal Protection for Patients with CKD in T2D

  0.25 credits

• • 

    

    Mikhail Kosiborod, MD

    Peer

  • 

    

    Michael Böhm, MD, FESC

    Peer

  13

  

  RestartResume

  The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topple Them Over?

  RestartResume

  The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topple Them Over?

  The 4 Pillars of Treatment in HFrEF: Does Risk of Hyperkalemia Threaten to Topp…

• • 

    

    Christie M. Ballantyne, MD

    Peer

  • 

    

    Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP

    Peer

  • 

    

    Joseph Saseen, PharmD, BCPS, BCACP, CLS

    Peer

  • 

    

    Karol Watson, MD, PhD

    Peer

  20

  CME/CE Broadcast Replay

  

  RestartResume

  Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central

  RestartResume

  Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central

  3.50 credits

  Adopting the New Therapeutic “Lineup” to Manage ASCVD - Central

  3.50 credits

• • 

    

    Ahmad Masri, MD, MS

    Peer

  • 

    

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

    Peer

  5

  

  RestartResume

  Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardiac Myosin Inhibition

  RestartResume

  Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardiac Myosin Inhibition

  0.25 credits

  Emerging Therapies in Hypertrophic Cardiomyopathy: The Potential Role of Cardia…

  0.25 credits